<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897139</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-Lym-2021</org_study_id>
    <nct_id>NCT04897139</nct_id>
  </id_info>
  <brief_title>Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT</brief_title>
  <official_title>Phase II Clinical Trial of Flu-Bu-Mel-E (Fludarabine, Busulfan, Melphalan and Etoposide) as Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase II clinical trial, we evaluate the efficacy and feasibility of conditioning&#xD;
      regimen of fludarabine 150mg/m2, busulfan 9.6mg/kg, melphalan 100mg/m2 and etoposide 800mg/m2&#xD;
      in patients with lymphoid malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>1 year after allo-HSCT</time_frame>
    <description>event defined as disease progression, relapse or death of any causes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year after allo-HSCT</time_frame>
    <description>event defined as death of any causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non relapse morality</measure>
    <time_frame>1 year after allo-HSCT</time_frame>
    <description>event defined as death of any causes except for disease progression or relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>1 year after allo-HSCT</time_frame>
    <description>event defined as disease progression or relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD-free or relapse-free survival</measure>
    <time_frame>1 year after allo-HSCT</time_frame>
    <description>event defined as disease progression or relapse, death of any cause, grade III-IV aGVHD or moderate to severe cGVHD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Lymphoid Neoplasm</condition>
  <arm_group>
    <arm_group_label>treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flu-Bu-Mel-E</intervention_name>
    <description>fludarabine 150mg/m2, busulfan 9.6mg/kg, melphalan 100mg/m2 and etoposide 800mg/m2</description>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  lymphoid malignancies&#xD;
&#xD;
          -  donor available: HLA matched sibling, unrelated donor or haplo-identical related&#xD;
             donor.&#xD;
&#xD;
          -  patients with ECOG &lt;3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inform consent not provided&#xD;
&#xD;
          -  ECOG &gt;=3&#xD;
&#xD;
          -  poor liver function (enzyme &gt;2N or bilirubin &gt;2N)&#xD;
&#xD;
          -  poor renal function (Scr &gt;2N)&#xD;
&#xD;
          -  poor cardiac function (EF &lt;45%)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong HU</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiong Hu</last_name>
    <phone>86-21-64370045</phone>
    <phone_ext>601818</phone_ext>
    <email>hj10709@rjh.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jieling Jiang</last_name>
    <phone>86-21-64370045</phone>
    <phone_ext>601818</phone_ext>
    <email>jjl12223@rjh.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Blood &amp; Marrow Transplantation Center, RuiJin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiong HU, M.D.</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>601818</phone_ext>
      <email>hj10709@rjh.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>May 22, 2021</last_update_submitted>
  <last_update_submitted_qc>May 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Head, BMT program, Rui Jin Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

